Supriya Lifescience Ltd

What Supriya Lifescience Ltd does

Supriya Lifescience Ltd is a publicly listed Indian pharmaceutical company founded in 1987 by Dr. Satish Wagh and headquartered in Mumbai, with manufacturing facilities concentrated in Maharashtra. The company develops, manufactures, and commercializes Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), with 38+ API products spanning anti-histamines, anti-allergics, anaesthetics, vitamins, anti-asthmatics, anti-hypertensives, analgesics, anti-malarials, and anti-gout therapies; it holds leadership positions in anti-histamines globally. Its API manufacturing is differentiated by capability in complex chemistries (Friedel Craft's Acylation, Grignard, Mannich, Ritter, chiral resolution, thermal ring expansion) that competitors cannot easily replicate, supported by DSIR-approved R&D in partnership with the Institute of Chemical Technology, Mumbai, and proprietary quality control infrastructure across a 10,000 sq.ft. laboratory.

The company generates revenue through four streams: (i) direct API sales to generic and innovator pharmaceutical companies globally, (ii) Finished Dosage Form sales including oncology, veterinary, and general formulations through the Ambernath facility, (iii) Contract Development and Manufacturing Organization (CDMO) services for regulated markets, and (iv) licensing and technology partnerships including a strategic vitamin B2 contract with DSM-Firmenich. It serves 2,000+ customers across 86 countries via direct B2B sales, with ~78% of revenue from exports and a high concentration in the anaesthetic segment (54% of revenue). Major regulatory approvals include USFDA, EDQM/EUGMP, WHO GMP, Health Canada, NMPA, and ANVISA, supported by 14 active USDMFs and 8 active CEPs. It also operates in novel therapeutics through academic partnerships (GelHeal wound care hydrogel, Quickblue oral cancer detection kit co-developed with Kalinga Institute of Industrial Technology).

The company is family-controlled, debt-free, and funds growth through internal accruals. Leadership transitioned to the next generation in August 2024 with Dr. Saloni Wagh as Managing Director and Shivani Wagh as Joint Managing Director. The go-to-market motion is enterprise field sales targeting innovator drug companies, large generic drug makers, and multi-national pharmaceutical corporations through direct relationships complemented by participation in global pharmaceutical industry events (CPHI, DCAT, Maghreb Pharma). FY26 revenue reached ₹827.87 crore with management guiding to ₹1,600 crore within three years, supported by the Module E production block (capacity +55%) and the ₹165 crore Ambernath formulations facility.

Name

Supriya Lifescience Ltd

Legal name

Supriya Lifescience Ltd

Website

https://supriyalifescience.com

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

251–500 employees

Short description

Supriya Lifescience Ltd is a Mumbai-based, publicly listed Indian manufacturer of 38+ Active Pharmaceutical Ingredients and Finished Dosage Forms, supplying 2,000+ customers across 86 countries with leadership in anti-histamines, anaesthetics, and vitamins via USFDA, EDQM, and WHO GMP-certified facilities.

Ownership category

akta.pro rank

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Infrastructure, Personnel, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (API) Sales: Core revenue stream from manufacturing and selling APIs across therapeutic segments including anti-histamines, anti-allergics, vitamins, anaesthetics, anti-asthmatics, decongestants, anti-hypertensives, analgesics, anti-malarials, and anti-gout products. The company has 38+ API products with leadership position in anti-histamines globally.
2. Finished Dosage Forms (FDF) Sales: Revenue from finished dosage forms including oncology products, veterinary products, and general category products. The company launched its Ambernath formulations facility and is expanding into the FDF segment.
3. Contract Development and Manufacturing Organization (CDMO): Contract manufacturing services for regulated global markets including Europe, Latin America, and North America. The company provides exclusive CMO services leveraging its 4 state-of-the-art facilities and regulatory approvals.
4. Licensing and Technology Partnerships: Revenue from technology partnerships and product licensing including agreements like the DSM-Firmenich contract for vitamin B2 API.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Core offering

Supriya Lifescience manufactures and supplies 38+ Active Pharmaceutical Ingredients (APIs) across therapeutic segments including anti-histamines, anti-allergics, anesthetics, vitamins, anti-asthmatics, analgesics, anti-malarials, anti-hypertensives, and anti-gout products. The company also offers Finished Dosage Forms (FDFs) covering oncology injectables, veterinary products, and general category medications, and provides Contract Development and Manufacturing Organization (CDMO) services for regulated global markets from its WHO GMP and EUGMP compliant facilities.

Product overview

Supriya Lifescience Ltd is a pharmaceutical company offering a diversified portfolio of 38+ Active Pharmaceutical Ingredients (APIs) across therapeutic segments including anti-histamines, anti-allergics, anti-asthmatics, anesthetics, vitamins, anti-hypertensives, analgesics, anti-malarials, and anti-gout medications. The company has expanded into Finished Dosage Forms (FDFs) including oncology injectables, veterinary products, and general medications through its Ambernath formulations facility. CDMO services provide contract manufacturing for regulated global markets. The portfolio also includes innovative therapeutics (GelHeal wound care and Quickblue oral cancer detection kit) developed through academic partnerships. The company operates cGMP compliant manufacturing facilities and serves customers in 86+ countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (API) Portfolio Portfolio of 38+ Active Pharmaceutical Ingredients spanning anti-histamines (Chlorphenamine Maleate, Cetirizine DiHCL, Pheniramine Maleate, Brompheniramine Maleate, etc.), anti-asthmatics (Salbutamol Sulphate, Levosalbutamol Sulphate), anaesthetics (Ketamine Hydrochloride, Esketamine Hydrochloride), vitamins (Riboflavin 5-Phosphate Sodium/Vitamin B2, Mecobalamin, Hydroxocobalamin), anti-hypertensives (Bisoprolol Fumarate), anti-anginal (Nicorandil), analgesics (Tramadol Hydrochloride), anti-malarials (Artemether, Lumefantrine), and anti-gout (Allopurinol). Supplied to generic and innovator pharmaceutical companies globally with USDMF, CEP, Health Canada, EUGMP, NMPA, and ANVISA certifications.
• Oncology Finished Dosage Forms (FDF) Portfolio Finished dosage form oncology portfolio of 20+ injectables including Azacitidine, Bortezomib, Carboplatin, Cisplatin, Docetaxel, Doxorubicin, Gemcitabine, Methotrexate, Oxaliplatin, and Paclitaxel. Targeted at hospital and oncology pharmaceutical buyers globally.
• Veterinary Finished Dosage Forms Portfolio Veterinary finished dosage forms including Adrenochrome, Chloramphenicol, Enrofloxacin, Ivermectin, and anti-parasitic chewable tablets (Afoxolaner, Fluralaner). Marketed to animal health pharmaceutical companies.
• General Category Finished Dosage Forms General category finished dosage forms including analgesics (Acetaminophen, Ibuprofen, Tramadol), anaesthetics (Ketamine, Sevoflurane, Isoflurane), contrast agents (Gadobutrol, Gadopiclenol), and other specialty products. Targeted at pharmaceutical companies seeking contract manufacturing for general therapeutic categories.
• CDMO Services Contract Development and Manufacturing Organization services offering API and Finished Dosage Form contract manufacturing for regulated global markets. Leverages four state-of-the-art facilities including the WHO GMP and EUGMP-compliant Ambernath formulations plant (commissioned 2026, ₹165 crore investment). Customers include pharmaceutical companies in Europe, Latin America, and North America seeking CDMO partners with USFDA, EUGMP, and WHO GMP approvals.
• GelHeal GelHeal is a breakthrough wound care product incorporating onsite Protein Matrix Technology developed in collaboration with KIIT-TBI. It is a protein-based crosslinked hydrogel for scar-free healing across third-degree wounds, cuts, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and surgical wounds. Targeted at hospitals, wound care clinics, and healthcare providers.
• Quickblue Oral Cancer Detection Kit Quickblue is a patented oral cancer detection kit developed with KIIT that enables rapid and accurate detection of oral cancer cells within minutes, offering a low-cost alternative to conventional biopsy methods. Targeted at dental clinics, oncology screening programs, and diagnostic laboratories.

Quantifiable outcome

• 50.2% YoY revenue growth to ₹276.53 crore in Q4 FY26
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Kalinga Institute of Industrial Technology (KIIT-TBI)coreStrategic or Co-development Partner · 7 November 2023Collaboration for development of GelHeal, a protein-based crosslinked Hydrogel for advanced wound care solutions. GelHeal incorporates onsite Protein Matrix Technology for scar-free healing suitable for various wound types. The partnership leverages KIIT's research capabilities with Supriya's manufacturing and commercialization expertise.
• Kalinga Institute of Industrial Technology (KIIT)coreStrategic or Co-development Partner · 25 October 2023Partnership to develop Quickblue, a first-of-its-kind oral cancer detection kit enabling rapid detection of oral cancer cells within minutes. The technology uses patented methodology and significantly reduces cost compared to conventional biopsy methods. Target market is 1-2% global market share.
• Plasma Nutrition, Inc. (US-based)minorStrategic or Co-development Partner · 3 August 2023Collaboration for protein technology development, representing Supriya's expansion into nutraceutical and protein-related pharmaceutical products. The partnership combines Plasma Nutrition's technology with Supriya's manufacturing capabilities.
• DSM-FirmenichcoreStrategic or Co-development Partner · 10 April 2023Strategic contract for vitamin B2 API supply and development. This partnership provides Supriya access to DSM-Firmenich's global distribution network and strengthens its position in the vitamins market segment.

Scale indicators17 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Laurus Labs: Indian-headquartered API and CDMO company with leadership positions in anti-retroviral, oncology, and other therapeutic APIs. Comparable to Supriya as a debt-conscious Indian API manufacturer expanding into formulations and CDMO for regulated markets.
• Jubilant Pharmova (Jubilant Generics): Indian pharmaceutical company with substantial API manufacturing plus CDMO and generics businesses serving global markets. Comparable to Supriya across API production, CDMO services, and regulatory-grade manufacturing for developed markets.
• Granules India: Indian vertically integrated API and finished dosage form manufacturer focused on generics for regulated markets. Comparable to Supriya in API-to-FDF integration, customer mix (global generic pharma), and export-driven revenue model.
• Piramal Pharma Solutions: Global CDMO with strong presence in API manufacturing, drug product development, and complex chemistry for innovator and generic clients. Comparable to Supriya's CDMO ambitions and complex chemistry capabilities (Friedel-Crafts, Grignard, chiral resolution).
• Divi's Laboratories: India-based leading manufacturer of active pharmaceutical ingredients and intermediates, with a strong custom synthesis (CDMO) business serving global innovator and generic companies. Closely comparable to Supriya in API manufacturing, complex chemistry capabilities, and regulated-market orientation.

Broad incumbents

• Cipla: Large Indian pharmaceutical company with global API and finished dosage form operations, particularly strong in respiratory therapeutics. Comparable to Supriya in respiratory/allergy API focus and regulated-market reach, but with a much broader finished product portfolio.
• Aurobindo Pharma: One of India's largest generic pharmaceutical companies with significant API manufacturing and a broad finished dosage portfolio across multiple therapeutic areas. Comparable to Supriya in API scale and export-led B2B model, but materially larger and more diversified.
• WuXi AppTec / WuXi STA: Large global CDMO offering API and finished dosage form contract manufacturing with extensive complex chemistry capabilities. Comparable to Supriya in CDMO service scope, complex hazardous chemistry scale-up, and global regulator-inspected facilities.
• Dr. Reddy's Laboratories: Major Indian pharmaceutical company with global API, generics, and proprietary products businesses. Comparable to Supriya in API expertise, USFDA-inspected facilities, and global B2B customer base, but operates at significantly greater scale and product breadth.

Regional players

• Sequent Scientific: India-based manufacturer of veterinary and animal health APIs and formulations. Comparable to Supriya's veterinary FDF portfolio and India-based API manufacturing footprint, though much more narrowly focused on animal health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Supriya Lifescience Ltd